Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.0852W HIGH $11.20
Volume
636.35 K
Value Traded
215.40 K
Short % Float
5.96%
+2.37%Week
-14.25%1 Month
+1,123.86%3 Month
+654.6%6 Month
-94.06%5 Year
-94.06%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
3.36 M
EPS (TTM)
-6.98
P/E Ratio
-
Ent. Value
1.53 M
Total Shares
1.32 M
Float Shares
880.00 K
Insiders
33.56%
Institutions
2.25%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
JUNS Catalyst Timeline
Dated clinical, regulatory and corporate events for Jupiter Neurosciences, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Jupiter Neurosciences, Inc.
65Total events
6Upcoming
14Tier-1 (high impact)
2024 to 2026Coverage
Upcoming catalysts 2
Event history 50
▼Reverse Stock SplitCorporate
1-for-75 reverse stock split approved by board and stockholders
▼Reverse Stock SplitCorporate
1-for-75 reverse stock split approved by board and stockholders
▲Partnership / LicenseALA-002Corporate
Jupiter Neurosciences signs definitive license agreement for exclusive U.S. rights to ALA-002
treatment-resistant PTSD, anxiety, and related neuropsychiatric conditionssource ↗
▲Partnership / LicenseALA-002Corporate
PharmAla grants Jupiter exclusive U.S. rights to ALA-002
neuropsychiatric disorderssource ↗
◆First Patient DosedJOTROLTrial
First patient dosing expected in near term
Parkinson's Diseasesource ↗
▲Trial InitiationJOTROLTrial
Phase 2a RESET trial active for JOTROL in Parkinson's Disease
Parkinson's Diseasesource ↗
▲Partnership / LicenseALA-002Corporate
PharmAla signs term sheet to license exclusive U.S. rights to ALA-002 to Jupiter Neurosciences
▲Management ChangeCorporate
Appointment of Kristopher Fishman and Sanjiv Lal to Nugevia Advisory Board
●Debt Royalty FinancingCorporate
Yorkville installment repayment commencement deferred to April 1, 2026
◆Oral PresentationPresentation
Corporate presentation at BIO Investment and Growth Summit 2026
◆Oral PresentationPresentation
Jupiter Neurosciences invited to present at private investor dinner at Mar-a-Lago
▲Trial InitiationJOTROLTrial
Multiple Phase 2 trials scheduled to launch within next 12 months
Alzheimer's, Parkinson's, MPS-I, Friedreich's Ataxia, MELASsource ↗
◆Oral PresentationPresentation
Live investor webinar and Q&A session hosted by RedChip Companies
◆Trial InitiationJOTROLTrial
Expected start of enrollment for Phase 2a trial of JOTROL in Parkinson's disease
Parkinson's diseasesource ↗
▲IND ClearanceJOTROLIND
FDA clearance of IND for Phase 2a trial of JOTROL in Parkinson's disease
Parkinson's diseasesource ↗
▲IND ClearanceJOTROLIND
FDA cleared IND for Phase 2a trial in Parkinson's disease
Parkinson's diseasesource ↗
▼Equity OfferingCorporate
Entered into agreements for up to $20 million flexible financing with Yorkville
▲Product LaunchNugeviaPost-Market
Jean Fallacara named third brand ambassador for Nugevia
longevitysource ↗
▲Product LaunchNugeviaPost-Market
Nugevia website launched and pre-orders opened for GLO, PWR, MND supplements
longevity and wellnesssource ↗
▲Product LaunchNugeviaPost-Market
Chris Webber named second brand ambassador for Nugevia
longevity supplementsource ↗
●Trial InitiationJOTROLTrial
Phase IIa Parkinson's disease trial initiation
Parkinson's diseasesource ↗
▲Product LaunchNugeviaPost-Market
Nugevia consumer product line launch
cognitive health, mitochondrial energy, skin vitalitysource ↗
◆First Patient DosedJOTROLTrial
First patient dosed in JNS115 Parkinson's Phase 2a trial
Parkinson's diseasesource ↗
▲Product LaunchJOTROLPost-Market
Launch of consumer longevity products (first three SKUs)
Longevity/Wellnesssource ↗
▲Product LaunchNugeviaPost-Market
Commercial launch of Nugevia consumer longevity product line
▲Partnership / LicenseCorporate
Strategic collaboration with Aquanova AG to develop longevity and healthspan products
▲Partnership / LicenseJOTROLCorporate
Partnerships with Zina Biopharmaceuticals and Catalent Pharma Solutions for Phase 2a study in Parkinson's disease
Parkinson's diseasesource ↗
▲Manufacturing MilestoneJOTROLCMC / Inspection
Manufacturing agreement with Catalent for JOTROL softgel capsules to support Phase 2a Parkinson's trial
Parkinson's diseasesource ↗
▲Partnership / LicenseJOTROLCorporate
Strategic partnership with Zina Biopharmaceuticals for Phase 2a Parkinson's trial
Parkinson's diseasesource ↗
◆Partnership / LicenseJOTROLCorporate
Ongoing business development and licensing discussions globally
▲Product LaunchJOTROLPost-Market
Direct-to-Consumer product launch of JOTROL-based products
longevity and aging marketsource ↗
Past FDA Catalysts and PDUFA Decisions
How JUNS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every JUNS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| JOTROL™ | Parkinson's Disease | Phase 2a | 2026-05-27 | statistically significant neuroprotective effects including rotarod performance and grip strengthRead More | Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson’s DiseaseRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Philipson Tomas JanDirector | Grant/Award | 536,428 536,428 held | $0.00 | 06/29/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in JUNS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in JUNS for Q2 2026. | ||||
JUNS Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How JUNS ranks across every disease it competes in
Competitive Position is a premium feature
See how JUNS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialJUNS News
JUNS▲ +7.4%today
Jupiter Neurosciences Announces First Patient Dosed in Phase 2a RESET Trial in Parkinson’s Disease and Exploration of Strategic Options to Maximize Shareholder Value
Jupiter Neurosciences has initiated patient dosing in its Phase 2a RESET trial for JOTROL™ in Parkinson's disease, marking a key clinical milestone. The trial aims to assess safety, pharmacokinetics, and biomarkers associated with the treatment. Additionally, the company is exploring strategic options to maximize shareholder value, including potential partnerships or asset sales.
Read more →JUNS▼ -26.1%on this news· ran to -40% by day 3
Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering
Jupiter Neurosciences, Inc. has announced a registered direct offering of 307,692 shares of common stock, aiming to raise approximately $2.0 million. The offering is set to close around August 24, 2026, pending customary conditions. This funding will support the company's ongoing clinical programs, including its lead product in a Phase IIa trial for Parkinson's disease.
Read more →JUNS▼ -25.7%on this news
Jupiter Neurosciences, Inc. Announces Reverse Stock Split
Jupiter Neurosciences, Inc. has announced a 1-for-75 reverse stock split approved by shareholders to enhance its stock price for Nasdaq compliance. The split will take effect on August 6, 2026, and will reduce outstanding shares significantly. Stockholders will receive cash for any fractional shares resulting from the split, and the company continues to advance its pipeline in neurological therapies.
Read more →JUNSJupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million
Jupiter Neurosciences has signed a definitive agreement with PharmAla Biotech for exclusive U.S. rights to ALA-002, a patented MDMA formulation. This transaction, valued at up to $100 million, allows Jupiter to diversify its CNS portfolio, adding a novel chemical entity alongside its ongoing Parkinson's disease program. The deal includes various milestone payments and aims to address treatment-resistant neuropsychiatric conditions.
Read more →JUNSPharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002
PharmAla Biotech has entered a definitive license agreement with Jupiter Neurosciences, granting exclusive U.S. rights to its lead drug candidate, ALA-002. The deal includes an upfront payment of $3.33 million and potential milestone payments totaling up to $100 million. PharmAla retains rights outside the U.S. and aims to advance ALA-002 internationally. This partnership is expected to enhance the development of ALA-002, targeting neuropsychiatric disorders.
Read more →JUNSJupiter Neurosciences Strengthens Board with Appointment of Dr. Tomas J. Philipson
Jupiter Neurosciences has appointed Dr. Tomas J. Philipson to its Board of Directors, effective June 26, 2026. Dr. Philipson, a former Acting Chairman of the White House Council of Economic Advisers, brings a wealth of experience in health economics and regulatory policy. His role is expected to enhance the company's strategic growth and shareholder value.
Read more →JUNSJupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson’s Disease
Jupiter Neurosciences has commenced patient enrollment for its Phase 2a RESET trial evaluating JOTROL™, an investigational treatment for Parkinson's Disease. This trial aims to address the unmet need for disease-modifying therapies, as current options only manage symptoms. The company anticipates first patient dosing soon, marking a significant milestone in their clinical development efforts.
Read more →JUNS▼ -12.2%on this newsshared move
Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering
Jupiter Neurosciences has successfully closed a $2.0 million registered direct offering, enhancing its financial position to support its Parkinson's Phase 2a trial. The company has also reduced its debt, which strengthens its balance sheet. CEO Christer Rosén highlighted the importance of this funding for upcoming milestones and future financing opportunities.
Read more →JUNS▼ -35.9%on this newsshared move
PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million
PharmAla Biotech has signed a term sheet granting exclusive U.S. rights to its MDMA therapeutic ALA-002 to Jupiter Neurosciences. The deal, valued at over $100 million, includes upfront payments and royalties. PharmAla retains rights outside the U.S. and aims to focus on its global strategy while benefiting from Jupiter's expertise in CNS therapies.
Read more →JUNS▼ -35.9%on this newsshared move
Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech Positions JUNS at the Forefront of Next-Generation MDMA-Based Therapeutics Following President Trump's April 18, 2026, Executive Order
Jupiter Neurosciences, Inc. has announced a $100 million term sheet for exclusive U.S. rights to ALA-002, a next-generation MDMA therapeutic from PharmAla Biotech. The transaction involves an upfront payment and outlines additional milestone payments tied to the drug's development and commercialization. ALA-002, recognized by the FDA as a Novel Chemical Entity, promises improved safety and therapeutic benefits. This acquisition positions JUNS strategically in the expanding market for psychedelic therapies, particularly for addressing conditions like PTSD and anxiety.
Read more →JUNSJupiter Neurosciences Appoints Kristopher Fishman and Sanjiv Lal to Nugevia™ Advisory Board
Jupiter Neurosciences has appointed Kristopher Fishman and Sanjiv Lal to its Nugevia™ Advisory Board, bringing extensive experience in pharmacy and wellness distribution. Their expertise highlights the company's focus on the growing market for practitioner-grade nutraceuticals, valued at over $1.5 billion in the U.S. The Nugevia™ line includes formulations backed by JOTROL™, which has shown improved bioavailability in clinical studies. The appointments aim to strengthen Jupiter's market presence in compounding and wellness sectors.
Read more →JUNSJupiter Neurosciences to Present at Emerging Growth Conference on April 2
Jupiter Neurosciences, Inc. (NASDAQ: JUNS) will present its clinical and commercial advancements at the Emerging Growth Conference on April 2, 2026. The company is focusing on neuroinflammation and healthy aging through its patented JOTROL™ platform. The presentation will be accessible live and via archived webcasts for investors and analysts.
Read more →JUNSJupiter Neurosciences to Present at BIO Investment and Growth Summit 2026
Jupiter Neurosciences will present at the BIO Investment and Growth Summit 2026, discussing its FDA-cleared Phase IIa clinical program for Parkinson's disease. The company aims to engage with investors while advancing its clinical pipeline and generating revenue through its Nugevia product. Management emphasizes a disciplined approach to execution and growth.
Read more →JUNSJupiter Neurosciences Invited to Present Clinical and Commercial Progress at Investor Dinner at Mar-a-Lago
Jupiter Neurosciences has been invited to present its clinical and commercial progress at an exclusive investor dinner at Mar-a-Lago. The company's management will discuss advancements in its Phase IIa Parkinson's program and its commercial strategy, including the Nugevia™ product. This event highlights Jupiter's commitment to transparency and investor engagement.
Read more →JUNSJupiter Neurosciences Amends Yorkville Installment Provisions to Align Capital With Clinical and Commercial Execution
Jupiter Neurosciences has amended its financing agreement with YA II PN, Ltd., deferring repayment commencement to April 2026 while maintaining core economic terms. This strategic decision supports the company's focus on its Phase II Parkinson's program and commercial efforts with Nugevia. The amendment reflects a commitment to align capital with clinical and commercial execution.
Read more →JUNS▼ -23.5%on this news
Jupiter Neurosciences Expands Nugevia™ Addressable Market with Focus on GLP-1 Users
Jupiter Neurosciences has announced a strategic initiative to expand its Nugevia™ product line, targeting users of GLP-1 weight loss therapies. This move aims to address the physiological demands associated with GLP-1-induced weight loss, offering solutions for metabolic resilience. The company's dual-engine strategy combines a clinical pipeline with direct-to-consumer offerings, enhancing its market position.
Read more →JUNSJoin Jupiter Neurosciences’ Exclusive Live Investor Webinar and Q&A Session on January 6
Jupiter Neurosciences, Inc. is hosting a live investor webinar on January 6, 2026, to discuss its scientific platform and clinical development plans. CEO Chister Rosén will highlight the company's lead asset, JOTROL™, which is advancing toward a Phase 2a trial for Parkinson's disease. The event will also cover Jupiter's dual-path strategy in both therapeutic and consumer markets.
Read more →JUNSJupiter Neurosciences Marks Transformational First Year as a Public Company, Entering 2026 with Powerful Clinical and Commercial Momentum
Jupiter Neurosciences, Inc. has marked its first year as a public company with significant achievements, including the advancement of its JOTROL™ platform into a Phase 2a clinical trial for Parkinson's disease and the launch of its Nugevia™ consumer product line. With FDA clearance for its trial and securing up to $20 million in strategic financing, the company is focused on enhancing its position in the $8 trillion longevity market. As it enters 2026, Jupiter is poised for growth, aiming for clinical data and revenue expansion, driven by its unique scientific approach.
Read more →About Jupiter Neurosciences, Inc.
Headquarters1001 NORTH US HWY 1, JUPITER, FL, 33477
BIOPHARMAWATCH ELITE PLUS
Trade the next JUNS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime